Information about sponsored clinical trials and result information are provided for informational purposes only and are not intended to promote any product or use. Clinical study results are intended to report the results of the study that were known at the time of the study's completion. The results therefore do not provide a comprehensive and current review of the safety and efficacy of any drug based upon all information available. Physicians and patients should refer to the current approved product labeling for information on approved indications in their country.
This information is not intended to replace the advice of a health care professional. Only a physician can determine if a specific medicine is the correct or best treatment option for a particular patient. If you have questions, please consult a health care professional.

A - B - C - D - E - F - G - H I - J - K - L - M N - O - P - Q - R - S T - U - V - W - X - Y - Z

Clinical study results Sanofi pharma, including Sanofi Genzyme – Letter N

GENERIC NAME

TRADE NAME

CONDITION

STUDY CODE

STUDY NAME

ACCESS TO STUDY / PROTOCOL

ACCESS TO RESULTS

NERISPIRDINE

Not marketed

Multiple Sclerosis

ACT10573

NA

NCT00772525

NERISPIRDINE

Not Marketed

Multiple Sclerosis

DRI10566

NA

EudraCT: 2008-001999-67

NOVEL INSULIN

Not Marketed

Diabetes Mellitus, Type 1

TDU10948

NA

NCT01053728

NOVEL INSULIN

Not Marketed

Diabetes Mellitus, Type 1

TDU10987

NA

NCT01053728


References:
*These study results were previously posted on GenzymeClinicalResearch.com
**This link replaces the same summary that was previously posted